[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:gm2-gangliosidosis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":35,"states":36},"GM2 Gangliosidosis",4,3,[8,16,22,28],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07054515","A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis",[12],"Phase 3","RECRUITING","2026-08-26T02:18:57.189473Z","2026-05-05T02:43:29.464579Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT00668187","A Natural History Study of the Gangliosidoses",[],"2026-08-26T02:19:22.562392Z","2026-05-13T02:55:06.039698Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT00029965","Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders",[],"2026-08-26T02:15:24.145250Z","2026-05-13T02:55:06.028754Z",{"nct_id":29,"title":30,"phases":31,"status":32,"updated_at":33,"content_modified":34},"NCT07082543","A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T02:31:11.254845Z","2026-05-05T02:43:28.672925Z",[],[37],{"state":38,"count":6,"slug":39},"Minnesota","minnesota"]